Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Aina Moll-Udina, Lucía Miguel Escuder, Inés Hernanz, Victor Llorenç, Alex Fonollosa, Miguel Cordero Coma, Maite Sainz de la Maza, Gerard Espinosa, J. Jacobo González Guijarro, Fernando Lopez Lopez, Carmen Alba-Linero, Marisa Hernández, Lucía Martínez Costa, Diego Celdrán Vivancos, Lena Giralt, Joseba Artaraz, Pablo Soler Bartrina, Margarita Jódar Márquez, Rosario García de Vicuña, Cristina Esquinas & Alfredo Adán. (2021) Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy. Ocular Immunology and Inflammation 29:7-8, pages 1591-1598.
Read now
Read now
Articles from other publishers (5)
Shizhao Yang, Zhaohao Huang, Xiuxing Liu, He Li, Lihui Xie, Xiaoqing Chen, Feng Wen, Dan Liang & Wenru Su. (2021) Comparative study of adalimumab versus conventional therapy in sight-threatening refractory Behçet’s uveitis with vasculitis. International Immunopharmacology 93, pages 107430.
Crossref
Crossref
Naomi Sugimura, Tsutomu Mizoshita, Tomoya Sugiyama, Shozo Togawa, Tomokatsu Miyaki, Taketo Suzuki, Satoshi Tanida, Hiromi Kataoka & Makoto Sasaki. (2019) Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet’s disease. Digestive and Liver Disease 51:7, pages 967-971.
Crossref
Crossref
S. Islam & Seonghyang Sohn. (2018) HSV-Induced Systemic Inflammation as an Animal Model for Behçet’s Disease and Therapeutic Applications. Viruses 10:9, pages 511.
Crossref
Crossref
Marko Barešić, Mirna Reihl, Mario Habek, Nenad Vukojević & Branimir Anić. (2018) Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab. Rheumatology International 38:7, pages 1301-1306.
Crossref
Crossref
. (2017) Infliximab. Reactions Weekly 1633:1, pages 403-403.
Crossref
Crossref